Keymed Biosciences, Inc. (2162) AI Stock Analysis

• Market Cap: HK$16.92B
• Dividend Yield: N/A
• Average Volume (3M): 2.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 964.40%
• EPS Growth: 65.90%
• Country: HK
• Employees: 1,258
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 298,735,570
• 10 Day Avg. Volume: 2,480,938
• 30 Day Avg. Volume: 2,154,553
• PEG Ratio: -0.34
• Price to Book (P/B): 3.07
• Price to Sales (P/S): 17.76
• P/FCF Ratio: -7.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$85.07
• Price Target Upside: 35.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: HK$59.00 ▼(-6.05% Downside)

Keymed Biosciences, Inc. faces significant challenges with ongoing losses and negative cash flows despite revenue growth. The technical indicators suggest bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The company's strong balance sheet is a positive aspect, but the path to profitability remains uncertain.

Keymed Biosciences, Inc. Business Overview & Revenue Model

Company Description

Keymed Biosciences, Inc. (2162) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics. Operating primarily in the biopharmaceutical sector, the company aims to address unmet medical needs through its robust pipeline of monoclonal antibodies and other biologics. With a strategic emphasis on oncology and autoimmune diseases, Keymed Biosciences is dedicated to advancing healthcare through cutting-edge science and technology.

How the Company Makes Money

Keymed Biosciences makes money through the development and commercialization of its proprietary therapeutics. The company's revenue model is primarily based on the sales of its biopharmaceutical products once they receive regulatory approval. Additionally, Keymed may engage in strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which can provide milestone payments, royalties, and co-development funding. These partnerships often enhance the company's financial stability and expand the market reach of its products. Research and development grants or subsidies from governmental and non-governmental organizations may also contribute to the company's earnings.

Keymed Biosciences, Inc. Financial Statement Overview

Summary

Keymed Biosciences, Inc. is experiencing revenue growth, but the company is still operating at a loss with negative net profit and EBIT margins. Despite a strong balance sheet with low leverage, negative cash flows and net losses pose risks to financial sustainability.

Income Statement

Keymed Biosciences, Inc. has shown significant revenue growth from 2022 to 2024, with revenue increasing from 100 million to 428 million. However, the company is still operating at a loss, with a negative net profit margin and EBIT margin. The gross profit margin is high, indicating good product profitability, but this is offset by high operating expenses leading to negative net income.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio below 0.5, indicating low leverage. However, the ROE is negative due to consistent net losses. The equity ratio is healthy, suggesting a strong asset base compared to liabilities, which is crucial for future growth and stability.

Cash Flow

The free cash flow remains negative, reflecting high capital expenditures and operating losses. There is an absence of operating cash flow, highlighting challenges in converting revenue into cash. The company has not demonstrated positive cash flow to net income ratios, which are critical for long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	872.19M	428.12M	354.10M	100.06M	110.27M	0.00
Gross Profit	830.25M	415.92M	317.22M	97.48M	93.07M	0.00
EBITDA	-312.61M	-574.46M	-269.77M	-259.25M	-3.86B	-135.09M
Net Income	-257.34M	-515.24M	-359.36M	-308.12M	-3.90B	-832.73M
Balance Sheet
Total Assets	4.63B	3.77B	3.88B	3.93B	3.93B	529.95M
Cash, Cash Equivalents and Short-Term Investments	2.80B	2.16B	2.72B	3.18B	3.52B	354.08M
Total Debt	872.30M	753.24M	418.71M	121.97M	39.26M	66.86M
Total Liabilities	1.44B	1.29B	896.11M	593.10M	289.07M	1.62B
Stockholders Equity	3.19B	2.47B	2.99B	3.34B	3.65B	-1.09B
Cash Flow
Free Cash Flow	-854.73M	-1.00B	-686.23M	-681.48M	-387.50M	-139.26M
Operating Cash Flow	-604.67M	-789.63M	-303.62M	-401.93M	-214.64M	-119.36M
Investing Cash Flow	-92.13M	67.71M	468.20M	-645.59M	-2.04B	-113.07M
Financing Cash Flow	905.48M	283.90M	72.13M	-8.06M	3.64B	7.40M

Keymed Biosciences, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 62.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Negative. The current price of 62.8 is below the 20-day moving average (MA) of 65.55, below the 50-day MA of 70.04, and above the 200-day MA of 50.55, indicating a neutral trend. The MACD of -3.63 indicates Positive momentum. The RSI at 38.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2162.

Keymed Biosciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	―	HK$11.11B	77.71	16.13%	―	48.38%	―
2171	―	HK$9.98B	―	-42.46%	―	1219.19%	25.15%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
2162	―	HK$16.92B	―	-8.79%	―	964.40%	65.90%
2157	―	HK$11.52B	-55.06	-21.42%	―	240.05%	-140.09%

Keymed Biosciences, Inc. Corporate Events

Keymed Biosciences Reports Strong Revenue Growth Amid Leadership Change

Keymed Biosciences Inc. reported a significant increase in revenue for the first half of 2025, driven by the successful sales of its core pipeline product, Stapokibart, which has received approvals for multiple indications. The company is advancing several Phase III clinical studies for Stapokibart and collaborating with AstraZeneca on the development of CMG901 for advanced solid tumors. Despite the positive revenue growth, the company experienced a loss, although it was substantially reduced compared to the previous year. The resignation of the Chief Financial Officer and Joint Company Secretary was also announced, marking a notable change in the company’s leadership.

The most recent analyst rating on (HK:2162) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.

Keymed Biosciences Schedules Board Meeting to Review Interim Results

Keymed Biosciences Inc. has announced a board meeting scheduled for August 26, 2025, to review and approve the interim financial results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder interests.

The most recent analyst rating on (HK:2162) stock is a Buy with a HK$60.93 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.